Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,621 to 1,640 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| RSV MAT Group - Mother vs Placebo Group - Mother: Number of Maternal Participants With at Least One All-cause MA-RTI From Day 1 to Day 181 Post-delivery | 317 of 3,557 144 of 1,771 | 0.8 points -0.9 to 2.3 | 5,328 | NCT04605159 A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers |
| RSV MAT Group - Mother vs Placebo Group - Mother: Number of Maternal Participants With at Least One SAE From Day 1 to Day 181 Post-delivery | 827 of 3,557 395 of 1,771 | 0.9 points -1.5 to 3.3 | 5,328 | NCT04605159 A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers |
| Cangrelor vs Clopidogrel: Incidence of ACUITY Major Bleeding | 145 of 2,662 91 of 2,650 | 2.0 points 0.9 to 3.1 | 5,312 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major | 4 of 2,662 9 of 2,650 | -0.2 points -0.5 to 0.1 | 5,312 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of GUSTO Severe / Life-threatening | 9 of 2,662 6 of 2,650 | 0.1 points -0.2 to 0.4 | 5,312 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of ACUITY Major Bleeding Without Hematoma >/= 5 cm | 43 of 2,662 29 of 2,650 | 0.5 points -0.1 to 1.2 | 5,312 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: serious adverse events | 48 of 2,662 55 of 2,650 | -0.3 points -1.0 to 0.5 | 5,312 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of Procedure Events [Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, Unsuccessful Procedure, New Thrombus or Suspected Thrombus, and/or Acute Stent Thrombosis] | 122 of 2,656 142 of 2,645 | -0.8 points -2.0 to 0.4 | 5,301 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of Stent Thrombosis | 5 of 2,654 16 of 2,641 | -0.4 points -0.8 to -0.1 | 5,295 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of All-cause Mortality or MI | 180 of 2,654 204 of 2,641 | -0.9 points -2.3 to 0.5 | 5,295 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of MI | 177 of 2,654 191 of 2,641 | -0.6 points -1.9 to 0.8 | 5,295 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of Stroke | 7 of 2,654 5 of 2,641 | 0.1 points -0.2 to 0.4 | 5,295 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of All-cause Mortality | 6 of 2,654 18 of 2,641 | -0.5 points -0.9 to -0.1 | 5,295 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR) | 185 of 2,654 210 of 2,641 | -1.0 points -2.4 to 0.4 | 5,295 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of IDR | 19 of 2,654 24 of 2,641 | -0.2 points -0.7 to 0.3 | 5,295 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Biomarker Cohort vs Non-biomarker Cohort: deaths from any cause | 364 of 618 3,780 of 4,661 | -22.2 points -26.3 to -18.2 | 5,279 | NCT05834348 A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. |
| Cangrelor vs Clopidogrel: Incidence of All-cause Mortality or MI | 213 of 2,647 233 of 2,629 | -0.8 points -2.3 to 0.7 | 5,276 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of MI | 189 of 2,647 201 of 2,629 | -0.5 points -1.9 to 0.9 | 5,276 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of All-cause Mortality | 35 of 2,647 45 of 2,629 | -0.4 points -1.1 to 0.3 | 5,276 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
| Cangrelor vs Clopidogrel: Incidence of Stroke | 6 of 2,647 5 of 2,629 | 0.0 points -0.2 to 0.3 | 5,276 | NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=82
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04605159-e50c2f3a",
"title": "RSV MAT Group - Mother vs Placebo Group - Mother: Number of Maternal Participants With at Least One All-cause MA-RTI From Day 1 to Day 181 Post-delivery",
"summary": "317 of 3557 against 144 of 1771; risk difference 0.8 points, 95% interval -0.9 to 2.3; NCT04605159, A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers",
"record": "/library/comparisons/NCT04605159-e50c2f3a",
"nct_id": "NCT04605159",
"kind": "outcome",
"participants": 5328,
"risk_difference": {
"value": 0.007810050628253559,
"lower": -0.00850209872708036,
"upper": 0.02318826622202931
},
"group_1": "317 of 3,557",
"group_2": "144 of 1,771",
"difference": "0.8 points",
"interval": "-0.9 to 2.3",
"trial_title": "A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers"
},
{
"id": "NCT04605159-ff2e7bca",
"title": "RSV MAT Group - Mother vs Placebo Group - Mother: Number of Maternal Participants With at Least One SAE From Day 1 to Day 181 Post-delivery",
"summary": "827 of 3557 against 395 of 1771; risk difference 0.9 points, 95% interval -1.5 to 3.3; NCT04605159, A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers",
"record": "/library/comparisons/NCT04605159-ff2e7bca",
"nct_id": "NCT04605159",
"kind": "outcome",
"participants": 5328,
"risk_difference": {
"value": 0.009461465427044624,
"lower": -0.014698086716277366,
"upper": 0.032982582247099906
},
"group_1": "827 of 3,557",
"group_2": "395 of 1,771",
"difference": "0.9 points",
"interval": "-1.5 to 3.3",
"trial_title": "A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=83",
"request_id": "2FlfNZ7Zubm9Pkcw"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant